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Abstract
Background: Severe anaemia requiring emergency blood transfusion is a common complication of malaria in children.
To ensure access for urgent blood transfusion, the World Health Organization has developed clear guidelines with
haemoglobin thresholds prevent unwarranted transfusion,. Few studies have reported outcome and haematological
recovery of children with severe malaria where transfusion practice complies with WHO recommendations.
Methods: A prospective observational study of survivors of severe and complicated malaria transfused in accordance
with WHO guidelines. Children were invited for review at one month post-discharge. Non-attendees were traced in the
community to ascertain survival.
Results: Outcome was assessed in 213 survivors. Those transfused were younger, had a higher base deficit, mean lactate
levels and a higher prevalence of respiratory distress. As expected mean admission haemoglobin (Hb) was significantly
lower amongst transfused [5.0 g/dL SD: 1.9] compared to non-transfused children [8.3 g/dL SD: 1.7] (p < 0.001). At
discharge mean Hb was similar 6.4 g/dL [SD: 1.5] and 6.8 g/dL [SD: 1.6] respectively (p = 0.08), most children remained
moderately to severely anaemic. At one month follow up 166 children (78%) returned, in whom we found no differences
in mean Hb between the transfused (10.2 g/dL [SD: 1.7]) and non-transfused (10.0 g/dL [SD: 1.3]) survivors (p = 0.25).
The major factors affecting haematological recovery were young age (<24 months) and concomitant malaria parasitaemia;
Hb being 8.8 g/dL [SD: 1.5] in parasitaemic individuals compared with 10.5 g/dL [SD: 1.3] in those without (p < 0.001).
Conclusion: This data supports the policy of rational use of blood transfusion, as proposed in the WHO guidelines, for
children with anaemia in areas where access to emergency transfusion is not guaranteed. We have provided empirical
data indicating that transfusion does not influence superior recovery in haemoglobin concentrations and therefore
cannot be justified on this basis alone. This may help resolve the disparity between international policy and current clinical
practice. Effective anti-malarial treatment at discharge may prevent reoccurrence of anaemia.
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Background
Annually approximately two billion people are exposed to
Plasmodium falciparum resulting in over 500 million clini-
cal cases and about one million deaths predominantly in
children less than five years living in the sub-Saharan
Africa (SSA) [1]. Malaria complicated with severe anaemia
(Hb<5 g/dL) is an important public health problem in
this patient population resulting in major life threatening
complications and is a major cause of mortality [2-4].
Anaemia secondary to malaria accounts for up to 70% of
all prescribed transfusions in malaria endemic SSA [5-7].
Previous studies have revealed that severe anaemia sec-
ondary to malaria without any other complications leads
to about 1% mortality, however, this rises to 16% when
complicated with respiratory distress (severe, sympto-
matic anaemia) and over 30% when both respiratory dis-
tress and coma also present[6].
For children with severe, symptomatic anaemia, it is now
recognized that an urgent blood transfusion is life sav-
ing[2]. However, in the many African hospitals blood
banking facilities are inadequate [8] and urgent transfu-
sions are often not possible [9]. In these circumstances
children have to wait while a replacement donor is found
and over 60% of deaths in children with severe malaria
anaemia occur before a transfusion can be given[2,10].
The majority of transfusions are, therefore, received by
children with stable, uncomplicated anaemia, for whom
the acute benefits of transfusion are unproven [9,11], One
study in Tanzania reported up to 50% avoidable transfu-
sions[11]. Often, what is is not considered is that the risks
of transfusion may outweigh the benefits, since blood
transfusions continue to be a major source of preventable
HIV infection [12]and other transfusion-transmissible
infections [2,3,13,14]. These risks are over and above
those due to transfusion reactions[14] and often not
detected due to poor haemovigilence. It is, therefore,
important to carefully delineate a group of patients who
need a blood transfusion.
The World Health Organization (WHO) guidelines,
which are largely based on expert opinion [15-17] and a
few previous studies [18], encourage rational use of
blood. These guidelines recommend that transfusion be
reserved only for children with absolute haemoglobin
(Hb) of ≤ 4 g/dL (profound anaemia) or haemoglobin of
4–5 g/dL plus respiratory distress in malaria endemic
areas and a higher cut off of 7 g/dl in areas of low malaria
transmission[19]. Adherence to the targeted use of trans-
fusion is hampered by the lack of clinical evidence that
this policy is safe in both the short and long term[20]. As
a result many children, who do not fulfil criteria for trans-
fusion, continue to receive transfusions in the belief that
both short and longer term outcome and haematological
recovery is improved.
Whilst there is compelling evidence to support use of
blood in children with profound anaemia and severe
anaemia with respiratory distress[2,3] evidence support-
ing transfusion avoidance in the group with severe anae-
mia (Hb 4–5 g/dL) without respiratory distress or
moderately severe anaemia (Hb < 7 g/dl) with life-threat-
ening complications [2,21,22] is less convincing. Further,
there are conflicting findings on the effect of transfusion
on haemoglobin recovery after discharge[2,21,22], which
may help inform a decision on the choice of whether or
not to conservatively manage these children. Setting aside
considerations of availability and safety, often overlooked
are the economic considerations of blood transfusion,
with an average cost of 30 US dollars in most localities,
rising up to 50 US dollars where voluntary non-remuner-
ated donors are used; most of these costs are recovered
from the patients or their families[23].
We have previously reported in-hospital outcome in chil-
dren with severe malaria including those with and with-
out symptomatic anaemia [24-27]. In this current study
we report haematological recovery at discharge, one
month post-admission and longer term survival in chil-
dren admitted with severe malarial anaemia complicated
by respiratory distress transfused in accordance to WHO
guidelines.
Methods
Setting
The study was conducted between May 2002 and January
2005 at the Kenya Medical Research Institute, Kilifi Dis-
trict Hospital, Kenya. Patients attend this hospital from a
well mapped Demographic Surveillance Site (DSS) in
which a census is conducted three times a year. Malaria is
endemic in Kilifi District, where falciparum parasitaemia
at the time of the study was present in over 30% of chil-
dren in the community and 46% of hospital admis-
sions[4,28]. Although many children are admitted with a
primary diagnosis of severe malaria complicated by some
degree of anaemia, the etiology of anaemia in this popu-
lation is complex[4,29]. The study area is one of the poor-
est in Kenya with 40% of children <5 years having
anthropometric measures of undernutrition, half with
biochemical markers of iron deficiency, 14% of children
within the DSS have sickle cell and almost 60% have α+
thalassemia deletion genotypes[13].
Participants
Demographic and clinical data were recorded on admis-
sion using a standard proforma. Children were eligible for
inclusion in this study if they manifested all of the follow-
ing features: P. falciparum parasitaemia (at any density), a
clinical feature of severe malaria (prostration, coma or res-
piratory distress) and metabolic acidosis (base deficit of
>8). Such children are at the greatest risk of death, includ-Malaria Journal 2008, 7:256 http://www.malariajournal.com/content/7/1/256
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ing the subgroup of children with symptomatic severe
malaria anaemia (Hb<5 g/dl in association with signs of
cardiorespiratory compromise).
Standard treatment
In accordance with WHO guidelines whole blood transfu-
sion (20 mls/kg of whole blood) was administered (with-
out diuretics) for children admitted with or subsequently
developing a Hb <4 g/dL or 4–5 g/dL if associated with
respiratory distress. Those with these features at admis-
sion were transfused immediately (early transfusion
group) while those without these features at admission
were transfused later if they developed these features
(delayed transfusion group). Children with features of
decompensated shock meeting above transfusion criteria
(early transfusion group) were administered pre-transfu-
sion management with 10 mls/kg fluid while awaiting
transfusion[26]. Children with a Hb>5 g/dl and respira-
tory distress were enrolled into intervention trials and
received volume expansion with saline, albumin or gelo-
fusine [24-27]. Following resolution of features of severe
malaria and once children were able to take and retain
oral medication, anti-malarial treatment was completed
with a full course of oral anti-malarial therapy. In accord-
ance with local national guidelines, the children received
a single dose of sulphadoxine-pyrimethamine (SP) up to
December 2003, and SP plus amodiaquine thereafter
when the national anti-malarial policy had changed.
Discharge and follow-up
Discharge from hospital was consequent upon establish-
ing both clinical and parasitological recovery (malaria
slide negative). Children were discharged with any level of
haemoglobin ≥ 4 g/dL as long as they did have respiratory
distress. At discharge all survivors received a course of iron
sulphate (20 mg/kg/day in three divided doses for 28 days
which was continued to complete three months), folate
(2.5/5 mg once day for body weight <10/>10 kg respec-
tively for 28 days and continued to complete three
months), and mebendazole (100 mg twice daily for three
days). Children reviewed before 21 days or after 35 days
were excluded from the primary analysis of haematologi-
cal recovery due to temporal effects on haemoglobin
recovery, but included in survival analysis. Follow-up
review included a full clinical assessment, anthropometric
measurement, full blood count, and a malaria slide.
Investigation of parasite genotyping was not performed
(to distinguish re-infection from recrudescence). Survival
of study children was also obtained by linking the clinical
data to the census data routinely done in the DSS refer-
ence to find out the long term progress of the study partic-
ipants. In this study, information from census done in
May 2005 was used.
Data analysis
Data was analysed using Stata version 8.2. Patients were
retrospectively classified as transfused or not transfused
and by compliance with follow-up. In children attending
follow-up within one month of post discharge admission,
discharge and follow-up characteristics of children who
were transfused according to WHO guidelines were com-
pared to those of their relatively less sick counterparts who
did not received blood transfusion, because they did not
fulfil the WHO criteria, by comparing means and standard
deviations for continuous variables and Chi2 or Fisher's
exact test for proportions. The haemoglobin at follow-up
was further categorized into <9.3 g/dL (WHO criteria for
anaemia) and >9.3 g/dL with those who failed to attain a
Hb of 9.3 g/dL classified as anaemic according to WHO
criteria[19]. Mantel-Haenszel methods were then used to
calculated crude odds ratios for association of various fac-
tors with anaemia at follow-up (i.e. Hb <9.3 g/dL) and a
logistic regression analysis done to determine independ-
ent associations. All variables with P-value < 0.25 at uni-
variate analysis were included in a logistic regression
analysis to identify independent determinants of haemo-
globin recovery and only those with a P value < 0.05 were
retained in the model. An a priori decision was made to
include age in each model due possible confounding
effect of age on incidence of anaemia in children with
malaria. Formal survival analysis was not performed,
instead survival was described as the proportion of cases
that were ascertained at discharge, follow-up and long-
term follow-up by DSS.
Results
Of the 241 participants in three intervention studies
[24,26,27]) admitted with severe malaria complicated by
metabolic acidosis, 213 (88%) survived to discharge and
166 (74%) attended follow-up. In hospital outcome has
been previously reported in detail[24,26,27] but is sum-
marized briefly for the whole cohort (n = 241) with
respect to early and delayed transfusion. The participants
included 65 (27%) children with profound anaemia (Hb
≤ 4 g/dL) or Hb 4–5 g/dL with respiratory distress (symp-
tomatic severe malaria anaemia-SSMA), 14 (6%) with Hb
between 4–5 g/dL without respiratory distress, 74 (30%)
children with moderate acidosis (base deficit 8–15) and
Hb>5 g/dL at admission and 88 (37%) children with
severe acidosis (base deficit > 15) and Hb>5 g/dL at
admission
Blood transfusion practice
Early transfusion group
Out of 241 children studied 65 (27%) had SSMA requir-
ing urgent transfusion according to WHO guidelines: 64
(98%) received a blood transfusion while one child diedMalaria Journal 2008, 7:256 http://www.malariajournal.com/content/7/1/256
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before transfusion could be obtained. Mortality was low,
only five (7.7%) children in this group died: four of these
children were in coma at admission and died within eight
hours of admission. All cases had a cardiorespiratory
arrest.
Delayed transfusion group
In addition 45 (18.6%) children received a whole blood
transfusion later during the course of their admission after
fulfilling the criteria outlined by WHO. Among the four-
teen children initially with severe anaemia (Hb of 4–5 g/
dL), but without respiratory distress, ten (71%) were
eventually transfused because they developed impaired
consciousness and/or respiratory distress. For children
with Hb> 5 g/dl with moderate or severe metabolic acido-
sis (base deficit >8 and >15 respectively) who were ini-
tially treated for shock with volume expansion, 5/74 (7%)
and 30/88 (34%) children respectively also went on to
receive a whole transfusion due to a fall in haemoglobin
below 5 g/dL. No differences in the proportion requiring
delayed transfusion were found between the different
resuscitation fluids. Four children (8.8%) in the delayed
transfusion group died; all had been admitted in deep
coma. No cases developed pulmonary oedema or a trans-
fusion reaction.
Haematological recovery of survivors
Of the 213 survivors, 166 (78%) patients returned for fol-
low-up assessment: 158 (74%) children were reviewed
between 21–35 days post discharge and eight (4%) were
reviewed outside this interval. Out of these eight children,
three attended earlier due to malarial fever (2) or malnu-
trition (1) and five were well, but attended on the wrong
date. Haematological recovery was assessed in 158 survi-
vors who subsequently attended follow-up within 22 to
35 days post-admission
Table 1: Baseline and follow-up characteristics of participants
Characteristic Survivors (n = 158)
Transfused Not transfused P
N (%) 61 (39) 97(61)
Age in months (median, IQR) 24(14–35) 31(21–43) 0.001
Proportion < 24 months (%) 24 48 0.002
Male sex (n, %) 30(49) 52(57) 0.59
Admission duration (days) (median, IQR) 5(4–8) 4(3–6) 0.13
Review interval (days) (median, IQR) 28 (25–31) 28(27–31) 0.88
Respiratory distress (n, %) 46(76) 54(56) 0.001
Lactate (mmol/L, mean SD) 5.8(4.5) 4.8(3.7) 0.06
Hypoglycaemia (<2.2 mmol/L) (n, %) 10(16) 21(22) 0.239
Severe acidosis (Base deficit >15) (n, %) 37(60) 45(46) 0.03
Haematological variables
Admission Hb (mean, SD) 5.0 (1.9) 8.3(1.7) 0.001
MCV (mean, SD) 75.6(6.3) 74.2(6.8) 0.09
MUAC (mean, SD) 13.8(1.3) 14.4(1.5) 0.02
Discharge Hb (mean, SD) 6.4 (1.5) 6.8(1.6) 0.08
Follow-up Hb (mean, SD) 10.2(1.7) 10.0(1.3) 0.25Malaria Journal 2008, 7:256 http://www.malariajournal.com/content/7/1/256
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Baseline characteristics
Baseline data are summarized in Table 1 with respect to
transfusion status. The mean admission Hb was 5.0 g/dL
[SD 1.9] in those receiving a blood transfusion while in
those not transfused, the mean Hb was 8.3 g/dL [SD 1.9].
Those transfused were younger, median age 25 months (SD
14–35) versus 36 months (SD 27–47); P < 0.001) and had
poorer nutritional status, mean mid-upper arm circumfer-
ence (MUAC) 13.6 cm [SD: 1.3] versus 14.5 cm [SD: 1.5];
(P < 0.001). Geometric mean parasitaemia was similar in
the transfused group 2.6 × 105 (95% Reference Range (RR)
1.7, 3.5) and non-transfused group 2.3 × 105 (95% RR 1.7,
2.9) (p = 0.62) as were sex, prevalence of hypoglycaemia or
mean corpuscular volume (MCV) (Table 1). However,
presence of respiratory distress, base deficit and mean lac-
tate levels were all significantly higher in the group of
patients who received a blood transfusion (Table 1).
At hospital discharge
Significant changes were observed in mean Hb between
admission and discharge which increased on average by
1.4 g/dl (SE 0.2) in those receiving a blood transfusion
and fell by a mean of 1.5 g/dl (SE 0.1) of Hb in the non-
transfused group. Although there were clear differences in
Hb at admission there were no differences in discharge Hb
in the two groups (F = 1.4; P = 0.23) (Table 1). At dis-
charge from hospital, 37/213 (17%) remained severely
anaemic (Hb 4–5 g/dL) and 100 (47%) children had
moderately severe anaemia (Hb 5–7 g/dl). All survivors
were aparasitaemic at time of discharge.
At follow-up review
Haematological recovery was identical in both groups
with no significant differences in the mean follow-up hae-
moglobin between those transfused and those not trans-
fused (p = 0.25) (Table 1). Overall, there was an 46%
mean increase of post-admission Hb at follow up, with
74% attaining an effective haematological recovery (Hb
>9.3 g/dL) and 89/158 (56%) achieving values greater
than 10 g/dl at follow up (Figure 1). For the 47 (22%)
non-attendees, there were no differences in the mean hae-
moglobins at admission (p = 0.16), discharge (p = 0.34),
and transfusion status or other marker of severity from
those that attended follow-up.
The presence of malaria parasitaemia at follow-up and
young age were the only factors independently associated
with follow-up haemoglobin. Nutritional status (deter-
mined by mid-upper arm circumference (MUAC) and
weight), mean corpuscular volume (MCV) and review
interval did not have a significant influence on the follow-
up haemoglobin.
Malaria parasitaemia at follow-up
Presence of malaria parasitaemia was found to be the
most significant determinant of haemoglobin recovery in
patients following admission with severe malaria (Figure
2). For those with parasitaemia, mean haemoglobin was
8.8 g/dL (SD: 1.5) compared to a mean of 10.5 g/dL (SD:
1.3) in aparasitaemic children; P < 0.001. This was not
influenced by mean haemoglobin at admission or dis-
charge, age, sex, review interval, MCV and MUAC as they
were not significantly different in the two groups. Of the
patients with parasitaemia at follow-up, 15/35 (43%)
were transfused while 20/35(57%) were not transfused (P
= 0.48). The odds ratio of a low haemoglobin (Hb <9.3 g/
dL) in cases with parasitaemia compared to no malaria
was 4.00 (1.61–8.42) (p = 0.002) and this remained sig-
nificant even after controlling for age, treatment received,
MUAC, MCV and sex (p = 0.001). Anti-malarial treatment
used at discharge had a significant influence on the fol-
low-up mean haemoglobin. Of the 158 patents included,
27/158 (17%) had sulfadoxine-pyrimethamine(SP)-amo-
diaquine combination while 131/158 (83%) had SP
alone. Children who had a combination therapy with SP-
amodiaquine had significantly higher mean haemoglobin
(10.9 g/dL SD 1.4) at the time of follow-up compared to
those who had SP alone (9.9 g/dL SD1.5) (p = 0.005).
Age
Age <24 months was found to be a significant determi-
nant of haemoglobin at admission (p < 0.001), discharge
(p = 0.008), and at follow-up (p = 0.01). Younger children
(age <24 months) had a lower Hb at admission (F = 15; p
< 0.001), discharge (F = 5; p = 0.008) and at review (F = 4;
p = 0.03). Children under 24 months old accounted for
31/61 (51%) of all transfusions; 14 given for SSMA and
17 delayed transfusions.
Follow-up in the community
Medium term survival was ascertained in the 166/213
(78%) patients who returned to follow-up, and the demo-
graphic surveillance was used to trace survival in those
who failed to attend follow-up review. Of the 47 non-
attendees 32 (68%) came from within the study area, of
whom we could confirm longer term survival on 30.
Twenty one were reported to be still alive and living in the
census area, 9/32 were still alive when they migrated out
of the study area and two were not traceable. This
increases the overall medium term survival to 196 (92%)
children with severe and life threatening malaria who
were managed conservatively with respect to blood trans-
fusion in accordance with WHO transfusion guidelines.
Discussion
This study demonstrates a number of important points.
First, if provides evidence that the WHO policy for ration-
ale use of blood transfusion in children with severe
malaria is justified. In these children both immediate and
longer-term child survival were optimized by strictly lim-
iting blood transfusions to a high-risk group with urgent
need of transfusion, and preventing unnecessary exposureMalaria Journal 2008, 7:256 http://www.malariajournal.com/content/7/1/256
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of those not warranting transfusion to the hazards of
blood transfusion.
Secondly, the study demonstrates that despite fall in hae-
moglobin during admission for those who are less sick
and do not fulfill the WHO criteria for transfusion, they
have satisfactory haematological recovery even if they are
discharged with moderate anaemia. They also do not have
increased risk of mortality either during admission or at
discharge. The absence of deaths among those children
who did turn up for one month follow-up but resident in
the study area at least six months after the last patient was
recruited allays fears of bias due to loss of follow-up.
Thirdly, this study shows that complete parasitological
recovery is very important for a satisfactory hematological
recovery. Once malaria parasitaemia is cleared the Hb
recovers rapidly with haematinic supplementation in this
study. We found that haematological recovery at one
month follow-up of these children was remarkable: 74%
attaining an effective haematological recovery (Hb >9.3 g/
dL) and 89/158 (56%) achieving values greater than 10 g/
dl. Neither blood transfusion nor nutritional status
affected mean Hb at follow-up. Although not directly
addressed by this study we suspect that anti-malarial drug
resistance was a major factor threatening hematological
recovery and is supported by similar studies in Kenya and
Tanzania [3,22]. Together, these emphasize the need for
an effective anti-malarial treatment to aid recovery.
Although we have limited data suggesting that a better
haematological recovery on the combination therapy of
SP-amodiaquine than those on SP alone, this finding
underscores the value of effective treatment for good hae-
matological recovery rather than blood transfusion. The
Post discharge haemoglobin recovery in children with severe malaria according to transfusion status Figure 1
Post discharge haemoglobin recovery in children with severe malaria according to transfusion status. Admission 
mean haemoglobin was lower in those transfused than those not transfused (p = 0.001), but there were no significant differ-
ences in the mean haemoglobins at discharge (p = 0.08) and at follow-up (p = 0.25).Malaria Journal 2008, 7:256 http://www.malariajournal.com/content/7/1/256
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availability of effective anti-malarial combination thera-
pies will not only result in less malaria and economic sav-
ings of inpatient treatment but may help to resolve some
of the current inadequacies of blood banking services.
The relative severity of anaemia in those less than 24
months is consistent with findings in other studies and is
likely to be a reflection of poor immunity to malaria
[3,4,15]. A study done in The Gambia showed a compar-
atively better recovery in children with Hb of 4–5 g/dL
receiving iron treatment than those who received a blood
transfusion [30]. While this difference could be due to
bone marrow suppression secondary to a blood transfu-
sion, children in Kilifi have a high prevalence of nutri-
tional deficiencies[13,31,32] and the similar
haematological recovery seen in our study for the two
groups when both are administered haematinics could be
due to the correction of iron deficiency.
In severe malaria this study provides some support that
blood transfusion can be avoided, and that while the
majority of children were moderately to severely anaemic
on discharge, most demonstrated a good haematological
recovery. This latter finding provides encouraging justifi-
cation for investigation for the use of the low volume
umbilical cord blood as an alternative source of blood for
transfusion[33]. Studies on the use of artificial haemo-
globins which have never been tested in this population
of patients but could provide immediate benefits to oxy-
gen carrying capacity where emergency blood is unavaila-
ble are probably warranted.
Post discharge haemoglobin recovery in children with severe malaria according to presence or absence of parasitaemia at fol- low up Figure 2
Post discharge haemoglobin recovery in children with severe malaria according to presence or absence of par-
asitaemia at follow up. Children with malaria parasitaemia at follow-up had similar mean haemoglobins to those without 
parasitaemia at admission and discharge. However, the mean haemoglobins at one month follow-up were higher in those with-
out parasitaemia (10.5 g/dL) than those with parasitaemia (8.8 g/dL) (p = 0.001).Malaria Journal 2008, 7:256 http://www.malariajournal.com/content/7/1/256
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A major limitation of this study was that these children
were in another clinical trial that was investigating the
safety and efficacy of volume expansion in children with
severe malaria and features of impaired perfusion. It is
thus not very clear whether fluid administration altered
the outcome in terms of the number who would have
required a blood transfusion. It is also unclear how the
WHO transfusion guidelines would work where frequent
re-assessment is not possible as this study found that 70%
of children with severe anaemia who were stable at admis-
sion were eventually transfused.
Conclusion
In conclusion, this study provides empirical data to sup-
port the rational use of blood transfusion in hospitalized
children with severe malaria, which may help resolve the
disparity between recommended policy and current clini-
cal practise. When the guidelines are followed, there is
neither an increase in mortality nor an increase in anae-
mia in children with severe malaria after discharge. Effec-
tive anti-malarial treatment at discharge prevents the
development of rebound anaemia.
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